Last reviewed · How we verify
Attenuated HAV Vaccine, L-A-1 Strain
This attenuated live vaccine stimulates immune responses against hepatitis A virus by introducing a weakened form of the virus that replicates in the body without causing disease.
This attenuated live vaccine stimulates immune responses against hepatitis A virus by introducing a weakened form of the virus that replicates in the body without causing disease. Used for Prevention of hepatitis A infection.
At a glance
| Generic name | Attenuated HAV Vaccine, L-A-1 Strain |
|---|---|
| Also known as | Hepatitis A Vaccine |
| Sponsor | Institute of Medical Biology, Chinese Academy of Medical Sciences |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The L-A-1 strain is a live attenuated hepatitis A virus vaccine that replicates in the gastrointestinal tract and induces both humoral (antibody) and cellular immune responses. The weakened virus triggers the production of neutralizing antibodies and memory B and T cells, providing long-term protection against wild-type hepatitis A virus infection without causing hepatitis.
Approved indications
- Prevention of hepatitis A infection
Common side effects
- Local injection site reactions (pain, erythema, swelling)
- Fever
- Gastrointestinal symptoms (diarrhea, nausea)
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: